[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647308":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":31,"centralContacts":10,"locations":35,"responsibleParty":56,"collaborators":58,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":10,"enrollmentInfo":73,"targetDuration":10,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":10,"overallStatus":81,"whyStopped":10,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"National Cancer Institute (NCI)","NIH",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational group I",null,"ONE DOSE GARDASIL9: Participants undergo cervicovaginal and anal swab self sample collection, blood sample collection, and complete questionnaires on study.",[13],"Other: Non-Interventional Study",{"label":15,"type":10,"description":16,"interventionNames":17},"Observational group II","TWO DOSE GARDASIL9: Participants undergo cervicovaginal and anal swab self sample collection, blood sample collection, and complete questionnaires on study.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Observational group III","UNVACCINATED: Participants undergo cervicovaginal and anal swab self sample collection, blood sample collection, and complete questionnaires on study.",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"OTHER","Non-Interventional Study","Non-interventional study",[9,15,19],[29,30],"Non-Interventional Observational Study","Noninterventional (Observational) Study",[32],{"name":33,"affiliation":5,"role":34},"Aimee Kreimer","PRINCIPAL_INVESTIGATOR",[36],{"facility":37,"status":10,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Agencia Costarricense de Investigaciones Biomédicas (ACIB)","Liberia","Guanacaste Province","50101","Costa Rica","CR",{"type":44,"coordinates":45},"Point",[46,47],-85.43779,10.63517,{"lat":47,"lon":46},[50,55],{"name":51,"role":52,"phone":53,"phoneExt":10,"email":54},"Carolina Porras","CONTACT","506-2668-1128","cporras@acibfunin.com",{"name":51,"role":34,"phone":10,"phoneExt":10,"email":10},{"type":57,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[59],{"name":60,"class":61},"Merck Sharp and Dohme LLC","UNKNOWN","100647308","a-scientific-evaluation-of-one-or-two-doses-of-a-vaccine-against-human-papillomavirus-long-term-follow-up-of-gardasil9-recipients-in-the-escuddo-study-estudio-de-comparacin-de-una-y-dos-dosis-de-vacunas-contra-el-virus-de-papiloma-humano-vph-100647308",false,"NCT07706673","ESCUDDO Long Term Follow Up","A Scientific Evaluation of One or Two Doses of a Vaccine Against Human Papillomavirus: Long Term Follow Up of Gardasil9 Recipients in the ESCUDDO Study (\"Estudio de Comparación de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano (VPH)\")","ESCUDDO LTFU","Inclusion Criteria:\n\n* \\* Participation in ESCUDDO base study\n\n  * Randomization (excluding the two participants who had major protocol deviations in the ESCUDDO base study) to the Gardasil9 1- and 2-dose arms\n  * A signed informed consent form for ESCUDDO LTFU.\n  * Opportunity to complete three total study visits\n  * LTFU Survey group:\n\n    * We will match the current ages of ESCUDDO LTFU trial participants when they attend their 9.5-year study visit (21 to 26 years of age)\n\nExclusion Criteria:\n\n* \\* Enrollment cannot occur beyond her 10 year study visit\n\n  * LTFU Survey group:\n\n    * They report they are pregnant;\n    * They report being vaccinated against HPV;\n    * The qualified healthcare personnel determining eligibility, in agreement with principal investigator, considers a reason that precludes participation; or\n    * They do not have an identification document",true,"FEMALE","18 Years",{"count":74,"type":75},9700,"ESTIMATED","OBSERVATIONAL","This study evaluates the long term protection provided by either one or two doses of the 9vHPV vaccine for participants who were part of the ESCUDDO study.",[79,80],"Human Papillomavirus Infection","Human Papillomavirus-Related Malignant Neoplasm","NOT_YET_RECRUITING","2026-08-19",{"date":84,"type":85},"2026-08-20","ACTUAL",{"date":87,"type":75},"2026-09-17",{"date":89,"type":75},"2031-01-15",{"name":5,"class":6},1]